Helperby Therapeutics Group Limited has announced a new partnership with GEM Global Yield LLC SCS, a Luxembourg-based private alternative investment group. Under the agreement, GEM will invest up to $75 million within 3 years of any public listing by Helperby.
Helperby is a private pharmaceutical company focused on developing multiple new antibiotic products to combat the global spread of Anti Microbial Resistance (AMR). This partnership will provide Helperby with the necessary funds to bring their innovative products to market.
According to Helperby Chairman and CEO James Phipson, this partnership is an important step in their plans to bring new antibiotics to the global market. Phipson also expressed his delight in GEM recognizing the value of Helperby’s portfolio.
GEM commented on their decision to invest in Helperby, stating that they recognized the unique and transformative approach Helperby offered. They also understood the opportunity to quickly, cheaply, and profitably bring a portfolio of new antibiotics to the market.
Helperby’s products are designed as combinations of existing approved antibiotics, which act synergistically to increase their effectiveness. This approach has been proven successful against malaria and AIDS/HIV and has been used in some of the world’s top-selling products. By using already-approved drugs, the risk, lead time for approvals, and cost of clinical trials are greatly reduced. This also allows for the discovery of new combinations and variations of existing ones, increasing the longevity of the products and associated patents.
Helperby currently has three products ready for immediate clinical trials, all of which target World Health Organization Critical or High Priority Pathogens. These products will initially be available as intravenous treatments for severe hospitalised patients, but Helperby also plans to develop broader indications and oral products in their portfolio. With a strong IP portfolio and development pipeline, Helperby is committed to providing a continual supply of new antibiotics.
Helperby Therapeutics is based in London, Dublin, and Bedford NH (USA) and was spun out from the Medical School at London’s St George’s Hospital, which is part of Britain’s National Health Service. The company’s founder, Professor Sir Anthony Coates, is a global authority on AMR and has been a leader in global efforts to combat it for many years. He also lectures on these subjects at the medical school of City St George’s, University of London.
GEM is a $3.4 billion alternative investment group with offices in Paris, New York, and Nassau (Bahamas). They manage a diverse set of investment vehicles focused on emerging markets and have completed over 600 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to small-mid cap management buyouts, private investments in public equities, and select venture investments.
More information about Helperby and GEM can be found on their respective websites. Helperby can be found at www.helperby.com, while GEM’s website is http://www.gemny.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.